相关临床试验
263
34 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
9
3.4%
已完成
173
65.8%
Enrolling By Invitation
5
1.9%
尚未招募
20
7.6%
招募中
26
9.9%
暂停
1
0.4%
终止
14
5.3%
Unknown
4
1.5%
撤回
11
4.2%
暂无批准数据
- New preclinical data presented at the 2026 AACR Annual Meeting demonstrates that opaganib enhances the efficacy of oxaliplatin plus doxorubicin chemotherapy in high-risk neuroblastoma by destabilizing n-Myc oncogene. - A separate study shows opaganib pre-treatment followed by low-dose diABZI potentiates STING-mediated effects and may augment anti-tumor immunity in triple-negative breast cancer models. - Opaganib, a first-in-class oral sphingosine kinase-2 inhibitor, has received FDA Orphan Drug and Rare Pediatric Disease designations for neuroblastoma treatment. - The drug has demonstrated safety and tolerability in over 470 people across multiple clinical studies and is currently being evaluated in a Phase 2 prostate cancer trial.
- New research from Penn State reveals that vitamin D deficiency in early pregnancy is associated with a fourfold increase in preterm birth rates and smaller infant size at delivery. - A complementary study by the University of Southampton demonstrates that maternal vitamin D supplementation during pregnancy leads to stronger, denser bones in children that persist until at least age 7. - Scientists emphasize that vitamin D monitoring should be prioritized alongside other essential nutrients during preconception and early pregnancy to promote optimal fetal development and long-term health outcomes.
- Hockey players who suffered three or more concussions had twice the risk of depression symptoms compared to those without concussion history, according to new Swedish research. - The study revealed concussed athletes faced 3.5 times higher risk of burnout symptoms including exhaustion, stress, concentration difficulties, and sleep disturbances. - Both male and female hockey players showed equally strong links between concussion and mental health issues, challenging previous assumptions about gender differences in recovery.
- Penn State researchers have demonstrated that sevelamer, an FDA-approved dialysis drug, can capture "off-target" antibiotics in the gut, potentially preventing bacteria from developing resistance. - The drug successfully bound vancomycin and daptomycin—two commonly prescribed antibiotics—in mouse models, blocking antibiotic activity and preventing resistance evolution in gut bacteria. - As 5-10% of intravenously administered antibiotics end up in the gastrointestinal tract where bacteria can develop resistance, this "anti-antibiotic" approach offers a novel strategy to preserve antibiotic effectiveness.
